Which therapeutic option for hepatitis C virus genotype 1?

@article{Brochot2015WhichTO,
  title={Which therapeutic option for hepatitis C virus genotype 1?},
  author={Etienne Brochot and François Helle and Catherine François and Sandrine Castelain and Dominique Capron and Eric Nguyen-Khac and Gilles Duverlie},
  journal={Scandinavian Journal of Gastroenterology},
  year={2015},
  volume={50},
  pages={470 - 478}
}
Abstract Objective. Sofosbuvir and simeprevir in combination with standard therapy are now available for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1. With boceprevir and telaprevir, four treatment options are, therefore, now available to clinicians. Phase 3 studies conducted with simeprevir and sofosbuvir compared sustained virological response (SVR) data with those obtained with standard combination therapy and did not include a control arm. It is… 
Phylogenetic analysis of a circulating hepatitis C virus recombinant strain 1b/1a isolated in a French hospital centre.
  • V. Morel, Faten Ghoubra, S. Castelain
  • Biology
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • 2016

References

SHOWING 1-10 OF 21 REFERENCES
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
TLDR
Relatively high percentages of real-life, treatment-experienced patients with HCV genotype 1 infection and cirrhosis respond to the combination of peginterferon and ribavirin with telaprevir or boceprevir, however, side effects are frequent and often severe.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
TLDR
Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
TLDR
The addition of boceprevir to standard therapy with peginterferon–ribavirin, as com pared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection.
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
TLDR
In treatment-experienced patients, 12, 24, or 48 weeks simeprevir in combination with 48 weeks PegIFn and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, andRBV and was generally well tolerated.
Boceprevir for untreated chronic HCV genotype 1 infection.
TLDR
The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection.
Boceprevir for previously treated chronic HCV genotype 1 infection.
TLDR
The addition of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virologic response in previously treated patients with chronic HCV genotype 1 infection, as compared with pegintersfer on-off therapy alone.
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
TLDR
In a phase 3 trial of patients with HCV genotype 1 infection who had relapsed after interferon-based therapy, the addition of simeprevir to PR was generally well tolerated, with an SVR12 rate of 79.2%.
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
  • S. Flamm, E. Lawitz, F. Poordad
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2013
...
...